Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced supportive phase 2a trial data. Gastrointestinal diseases are one of the Japanese ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Coursera Inc. (NYSE:COUR) is one of the small cap stocks with the highest upside potential. On April 23, Coursera reported its financial results for Q1 2026, highlighted by a 9% year-over-year ...

Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune tolerance CHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company ...

We list the best IDE for Python, to make it simple and easy for programmers to manage their Python code with a selection of specialist tools. An Integrated Development Environment (IDE) allows you to ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

This repository provides unofficial binary wheels for Pygame for Python on Windows. The files are unofficial (meaning: informal, unrecognized, personal, unsupported, no warranty, no liability, ...

Coursera (COUR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Ewan has been a content writer since 2020, and loves nothing more than discussing all things gaming. While he's been playing games all his life, he has a particular interesting in anything even ...

CNP-104 is a biodegradable nanoparticle that previously received fast track designation from FDA in January 2022, which would eventually make it eligible for accelerated approval and priority review.